Stephen Miyasato, MD
Internal Medicine · Aiea, HINPI 1477536563
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 353 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,905 and has fallen 59.8% since, to $1,169 in 2025. Among internal medicine clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $26.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$1K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Amarin Pharma, Inc.$978
- Radius Health, Inc.$476
- plus $3K from 14 others
What the payments were for
- Food & beverage$9,482100%
- Education$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 128 | $1,718 |
| Amgen | 37 | $1,451 |
| Lilly USA, LLC | 45 | $1,158 |
| AstraZeneca | 41 | $1,145 |
| Amarin Pharma, Inc. | 37 | $978 |
| Radius Health, Inc. | 17 | $476 |
| Teva Pharmaceuticals USA, Inc. | 7 | $410 |
| Abbott | 3 | $389 |
| Insmed, Inc. | 4 | $372 |
| Bayer | 3 | $356 |
| Boehringer Ingelheim | 11 | $241 |
| Pfizer | 5 | $145 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $129 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| Exact Sciences | 1 | $118 |
| Jazz Pharmaceuticals Inc. | 1 | $115 |
| Merck | 5 | $83 |
| GSK | 4 | $76 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Boston Scientific | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,521 in reported general payments places this provider in the 90th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 310 | $501,421 |
| JardianceEmpagliflozin | 189 | $274,320 |
| RybelsusSemaglutide | 57 | $139,836 |
| ProliaDenosumab | 57 | $98,919 |
| FarxigaDapagliflozin Propanediol | 40 | $54,270 |
| MounjaroTirzepatide | 28 | $52,932 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 28 | $45,207 |
| TrulicityDulaglutide | 19 | $43,675 |
| VascepaIcosapent Ethyl | 53 | $43,329 |
| JanuviaSitagliptin Phosphate | 22 | $32,247 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $19,983 |
| Atorvastatin Calcium | 560 | $16,124 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $13,701 |
| KerendiaFinerenone | 12 | $7,209 |
| Rosuvastatin Calcium | 138 | $6,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,718 | $641,257367 claims |
| Boehringer IngelheimJardiance | $241 | $274,320189 claims |
| AmgenProlia | $1,451 | $98,91957 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,158 | $96,60747 claims |
| MerckJanumet Xr, Januvia | $83 | $77,45550 claims |
| AstraZenecaFarxiga | $1,145 | $54,27040 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $76 | $26,03537 claims |
| BayerKerendia | $356 | $7,20912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Aiea
- Alan OkiAiea$13K
- Joel KobayashiAiea$11K
- Roy EbisuAiea$11K
- Francis ButoAiea$10K
- Mark NishiharaAiea$9K
- Malissa Iida-TakashimaAiea$9K
- Michael MiharaAiea$8K
- Scott StromattKamuela$385K
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.